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Interaction between Polyketide Synthase and
Transporter Suggests Coupled Synthesis and
Export of Virulence Lipid in M. tuberculosis
Madhulika Jain, Jeffery S. Cox*
Department of Microbiology and Immunology, University of California, San Francisco, California, United States of America
Virulent mycobacteria utilize surface-exposed polyketides to interact with host cells, but the mechanism by which
these hydrophobic molecules are transported across the cell envelope to the surface of the bacteria is poorly
understood. Phthiocerol dimycocerosate (PDIM), a surface-exposed polyketide lipid necessary for Mycobacterium
tuberculosis virulence, is the product of several polyketide synthases including PpsE. Transport of PDIM requires
MmpL7, a member of the MmpL family of RND permeases. Here we show that a domain of MmpL7 biochemically
interacts with PpsE, the first report of an interaction between a biosynthetic enzyme and its cognate transporter.
Overexpression of the interaction domain of MmpL7 acts as a dominant negative to PDIM synthesis by poisoning the
interaction between synthase and transporter. This suggests that MmpL7 acts in complex with the synthesis machinery
to efficiently transport PDIM across the cell membrane. Coordination of synthesis and transport may not only be a
feature of MmpL-mediated transport in M. tuberculosis, but may also represent a general mechanism of polyketide
export in many different microorganisms.
Citation: Jain M, Cox JS (2005) Interaction between polyketide synthase and transporter suggests coupled synthesis and export of virulence lipid in M. tuberculosis. PLoS
Pathog 1(1): e2.
Introduction
Mycobacterium tuberculosis, the causative agent of tuber-
culosis, has an extraordinary ability to resist the bactericidal
mechanisms of the human immune system [1]. The integrity
of the complex mycobacterial cell wall and its associated
lipids has long been thought to be important for virulence [2–
6]. This complex lipid metabolism is reflected in the
enormous capacity of M. tuberculosis for polyketide lipid
synthesis: there are at least 24 different polyketide synthases
and numerous lipid modification enzymes encoded in its
genome [7]. Recent evidence has shown that surface-exposed
polyketides, associated with the outer leaflet of the cell wall,
are central to the pathogenesis of M. tuberculosis [8–11]. Genes
involved in the synthesis and transport of these polyketides
are required for bacterial growth and virulence in mice.
Furthermore, these lipids have been shown to provide a
direct physical barrier to host-induced damage [12], as well as
to modulate the immune response to infection by altering
cytokine profiles in macrophages [13–15].
Many of the surface-exposed polyketides in M. tuberculosis
require active transport from their site of synthesis in the
cytoplasmic membrane to the cell surface. Unfortunately,
little is known about the mechanism of polyketide secretion.
MmpL7, a member of the MmpL (mycobacterial membrane
protein large) family of proteins in M. tuberculosis, was the first
MmpL shown to be required for the transport of a specific
polyketide, phthiocerol dimycocerosate (PDIM) to the cell
surface [8]. A number of genes involved in PDIM biogenesis
have also been identified [16–18], and the biosynthetic
pathway is shown in a schematic in Figure 1A. The PpsA–E
gene products extend straight chain fatty acids to phthiocer-
ol, and the mycocerosic acid synthase (Mas) enzyme catalyzes
the addition of methyl branches to synthesize mycocerosic
acids [16,17,19]. The enzymes FadD26 and FadD28 are
thought to be AMP ligases that activate straight chain fatty
acids for transfer to the Pps and Mas enzymes [20]. Finally,
both MmpL7 and DrrC are required for transport of PDIM to
the cell surface [8,10]. MmpL8, another MmpL family
member, has been shown to be required for the biogenesis
and transport of sulfolipid-1 (SL-1) [9,11]. Given the apparent
specificity in MmpL-mediated transport, it is likely that the
other eleven MmpL proteins encoded by the M. tuberculosis
genome transport specific lipids that may be involved in
bacterial virulence.
MmpLs belong to a broader class of proteins termed RND
(resistance, nodulation, and cell division) permeases [21].
MmpL7, like most RND transporters, is predicted to contain
twelve transmembrane (TM) domains with two non-TM
domains between TM #1 and #2 (domain 1) and between
TM #7 and #8 (domain 2) (Figure 1B). The structure of AcrB, a
well studied RND transporter involved in multidrug efflux in
Escherichia coli, has been determined, and its non-TM domains
have been localized to the periplasm [22,23]. AcrB interacts
with an outer membrane protein, TolC, to expel a variety of
drugs from the cytoplasmic membrane across the entire cell
wall [24,25]. Since MmpLs are similar in predicted topology to
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RND permeases, and are required for the transport of
cytoplasmic polyketide substrates, we reasoned that they
may also interact with other proteins that are involved in the
transport of lipids to the cell surface. To better understand
the transport of PDIM to the outer leaflet of the cell wall, we
probed for interactors of MmpL7. Surprisingly, we found an
interaction between MmpL7 domain 2 and the PDIM
synthetic enzyme PpsE that is required for the final step of
phthiocerol synthesis. Because PpsE acts in the cytoplasm,
where PDIM is synthesized, the interaction suggests that
MmpL7 domain 2 is accessible to the cytoplasm. We propose
that MmpL7 acts as a scaffold to recruit PDIM synthetic
machinery, forming a complex that coordinates lipid syn-
thesis and transport.
Results
Identification of MmpL7–PpsE Interaction
To determine the mechanism of PDIM transport to the
surface of M. tuberculosis bacilli, we first sought to identify
components that interact with the two large non-TM domains
of MmpL7 using a yeast two-hybrid approach (Figure 1B) [26].
We created two ‘‘bait’’ constructs to express either an MmpL7
domain 1 or an MmpL7 domain 2 fusion with the LexA DNA-
binding protein in yeast. Although MmpL7 domain 1
activated transcription of both the LEU2 and lacZ yeast
reporters on its own, MmpL7 domain 2 expression did not
auto-activate the reporters (Figure 2A and 2B) and thus was
suitable for screening an M. tuberculosis genomic ‘‘prey’’
library for interactors. We identified positive library clones
by selecting for growth on medium lacking leucine followed
by blue–white screening on plates containing X-gal. Surpris-
ingly, our screen identified an interaction between MmpL7
domain 2 and a 373-amino-acid fragment of PpsE, the enzyme
required for the final step of phthiocerol synthesis (Figure 2).
A number of observations suggest that the interaction
between MmpL7 domain 2 and PpsE is meaningful. First,
PpsE was one of the strongest interactors identified in the
screen as judged by blue color on indicator plates as well as
quantitative b-galactosidase assays (.100-fold increase over
controls; Figure 2B). Second, the interaction between MmpL7
domain 2 and PpsE is specific because PpsE did not interact
with either LexA alone or with domain 2 of the homologous
transporter MmpL8 (Figure 2A and 2B). Western blot analysis
using anti-LexA antibodies indicated that the MmpL8
domain 2 and MmpL7 domain 2 baits were expressed at
equivalent levels (data not shown). Finally, as PpsE is required
for the synthesis of PDIM and MmpL7 is required for the
transport of PDIM [8], the interaction between PpsE and
MmpL7 suggested the intriguing possibility that PDIM syn-
thesis and transport are coupled.
To confirm the interaction between MmpL7 domain 2 and
PpsE in vitro and test the interaction’s role in vivo, we first
sought to generate a mutant MmpL7 domain 2 that does not
interact with PpsE. We used a reverse yeast two-hybrid
approach [27] to identify single amino acid changes in
MmpL7 domain 2 that disrupt its interaction with PpsE. We
engineered our original MmpL7 domain 2 bait vector to
include a C-terminal GFP fusion to easily avoid mutations
that resulted in protein truncations. We randomly mutagen-
ized MmpL7 domain 2 using error-prone PCR, introduced
Figure 1. PDIM Synthesis and Export Pathway and Topology of MmpL7
(A) Schematic of the known steps in the PDIM synthesis and transport
pathway. PpsA–E and Mas are polyketide synthases that extend fatty
acids to phthiocerol and mycocerosic acids, respectively [16,17]. These
are then esterified to produce PDIM. MmpL7 and DrrC are required for
the transport of PDIM to the cell surface [8,10]. R is¼O (keto) or –OCH3
(methoxy).
(B) Predicted membrane topology of MmpL7 indicating the two non-TM
domains 1 and 2.
DOI: 10.1371/journal.ppat.0010002.g001
PLoS Pathogens | www.plospathogens.org September 2005 | Volume 1 | Issue 1 | e20013
Coupled Polyketide Synthesis and Transport
Synopsis
Pathogenic microbes have developed sophisticated strategies to
evade the human immune system and establish infection. Myco-
bacterium tuberculosis, the causative agent of tuberculosis, exports a
wide array of lipid virulence factors to the cell surface and into host
cells, where they can interact with the host immune system. A
strategy to combat M. tuberculosis infections may be to interfere
with the bacterium’s ability to make and secrete these lipids. In the
authors’ efforts to understand this process, they have found that
synthesis and export of a key lipid virulence factor are coupled. They
propose that the synthesis and transport proteins form a complex
that promotes efficient lipid export. The coordination of lipid
synthesis and export, analogous to co-translational translocation of
secreted proteins, may be a general mechanism employed by many
different microorganisms to actively transport hydrophobic mole-
cules from cells.
these constructs into yeast cells bearing the PpsE prey
plasmid, and screened for colonies that were both white on
X-gal indicator plates and GFP positive. Colonies with the
desired phenotype were isolated and the bait plasmids were
recovered, retested, and sequenced. Interestingly, of the 12
plasmids that contained mutations that led to single amino
acid changes in MmpL7 domain 2, nine clustered in a 50-
amino-acid region of the protein (Figure 3A). Eight of the
mutations led to substitutions with proline or glycine, which
are more likely to be structurally disruptive and possibly lead
to global unfolding of the protein. The four remaining
mutants, W571R, Y594H, Y594C, and I611S (amino acid
numbers correspond to positions in full-length MmpL7) were
reconstituted into the original bait vector lacking GFP and
assayed for interaction both on X-gal plates and by liquid b-
galactosidase assays (Figure 3B). Western blot analysis
confirmed that these changes did not lead to differences in
protein levels (data not shown). Since the I611S mutation is
the most conservative mutation and leads to a large reduction
in the interaction with PpsE, this mutant was chosen for
subsequent analysis.
MmpL7 Domain 2 Interacts with PpsE In Vitro
To independently test the interaction between MmpL7
domain 2 and PpsE identified in the two-hybrid screen, we
performed in vitro GST pulldown experiments (Figure 3C).
Glutathione agarose beads coated with MmpL7 domain 2
GST fusion protein were incubated with lysates from M.
smegmatis cells expressing full-length, myc-tagged PpsE. PpsE
interacted with beads coated with MmpL7 domain 2 but not
with beads containing only GST protein (Figure 3C, lanes 2
and 3). Furthermore, the I611S mutation led to drastically
reduced binding with PpsE (lane 4). Coomassie staining of
proteins eluted from the beads demonstrated that equal
amounts of MmpL7 domain 2 and the I611S mutant protein
were present during the pulldown (data not shown).
Importantly, while the I611S mutation had a large effect on
PpsE binding, we consistently observed low-level residual
binding both by GST pulldown and yeast two-hybrid assays.
Taken together, our results demonstrate that MmpL7 domain
2 can specifically interact with PpsE in vitro.
MmpL7 Domain 2 Inhibits PDIM Synthesis In Vivo
We next sought to determine whether the interaction
between MmpL7 and PpsE occurs in vivo. Since MmpL7 is an
integral membrane protein and PpsE is most likely present in
the cytoplasm, we reasoned that MmpL7 domain 2 must be
accessible to the cytoplasm in order to interact with PpsE.
Overexpression of MmpL7 domain 2 in the cytoplasm would
then act as a dominant negative by titrating PpsE away from
endogenous full-length MmpL7.
To this end we expressed MmpL7 domain 2 in the
cytoplasm of wild-type cells, under the control of the
constitutive groEL2 promoter. To assay PDIM synthesis and
transport, we labeled cells with 14C-propionate (which is
incorporated into PDIM) and extracted surface-exposed
lipids from the cell wall. In this procedure, radioactively
labeled cells were resuspended in hexanes and then harvested
by centrifugation to yield a supernatant fraction that
contained surface-exposed lipids, and a pellet fraction that
contained the remaining total lipids associated with the cell.
Lipids from both fractions were extracted and separated by
thin layer chromatography (TLC) in order to resolve PDIM
(Figure 4A). As expected, in wild-type cells PDIM was present
in both the pellet and supernatant fractions (Figure 4A, lanes
1 and 2), demonstrating that PDIM is both synthesized and
transported. In a PDIM synthesis mutant, fadD28, PDIM was
absent from both fractions (lanes 3 and 4), whereas in the
PDIM transport mutant, mmpL7, PDIM was present only in
the pellet fraction (lanes 5 and 6). Interestingly, over-
expression of MmpL7 domain 2 in wild-type cells resulted
in more than 98% inhibition of PDIM synthesis (lanes 7 and
8). Although overexpression of MmpL7 domain 2 did not
cause any growth defects (data not shown), it was possible that
Figure 2. MmpL7 Domain 2 Interacts with the PDIM Synthesis Enzyme
PpsE
(A) Yeast two-hybrid reporter strains harboring the indicated bait and
prey plasmids were streaked onto solid media with or without leucine.
Growth on leucine-negative plates indicates a positive interaction.
MmpL7d2, MmpL7 domain 2; MmpL8d2, MmpL8 domain 2.
(B) The same strains as in (A) were transferred onto X-gal-containing
indicator plates (inset), and reporter activity was quantified from liquid
cultures using b-galactosidase assays.
(C) Linear representation of full-length PpsE protein (1,488 amino acids)
with the MmpL7 interaction region denoted. Catalytic domains of PpsE
are also shown. ACP, acyl carrier protein; AT, acyl transferase; CE,
condensing enzyme; KS, ketoacyl synthase.
DOI: 10.1371/journal.ppat.0010002.g002
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it had a nonspecific effect on lipid synthesis. To confirm that
overexpression of MmpL7 domain 2 specifically inhibits
PDIM synthesis, we monitored SL-1, which like PDIM also
incorporates propionic acid, in the same extracts and
observed no differences in SL-1 synthesis or transport (Figure
4A).
The effect on PDIM synthesis was surprising, as mmpL7
cells are still able to synthesize PDIM; thus, a simple
prediction would have been that a dominant negative form
of MmpL7 would inhibit PDIM transport not synthesis.
Although the mechanism of the dominant negative effect of
domain 2 is unclear, the specific effect of MmpL7 domain 2
on PDIM synthesis, in addition to its specific interaction with
PpsE, suggests that MmpL7 domain 2 interacts with PpsE in
vivo.
To test whether the dominant negative effect of MmpL7
domain 2 on PDIM synthesis is indeed due to its interaction
with PpsE, we overexpressed the I611S mutant form that fails
to interact with PpsE. The I611S mutation was generated in
the MmpL7 domain 2 overexpression construct and intro-
duced into wild-type M. tuberculosis cells. Although MmpL7
domain 2 I611S was expressed at levels similar to those of the
wild-type version, it was unable to inhibit PDIM synthesis to
the same extent (Figure 4B). PDIM synthesis in this strain was
approximately 50% of wild-type, consistent with the severely
reduced, but not completely abolished, interaction of the
I611S mutant MmpL7 domain 2 with PpsE. This result
strongly suggests that MmpL7 domain 2 inhibits PDIM
synthesis via direct inhibition of PpsE.
We reasoned that if MmpL7 interacts with PpsE in vivo to
coordinately synthesize and transport PDIM, then an MmpL7
mutant that does not interact with PpsE may be defective for
PDIM transport. To test this we introduced the I611S change
in the context of full-length MmpL7 and expressed the wild-
type and mutant forms of MmpL7 in an mmpL7 strain. We
found that both forms were able to complement the PDIM
transport defect (Figure 4C, lanes 8 and 10). Therefore,
although the I611S mutation led to decreased interaction
between MmpL7 domain 2 and PpsE in earlier experiments,
in the context of full-length protein this mutation alone was
not sufficient to decrease MmpL7 activity in vivo. Although
the reason is unclear, this could be because MmpL7 has
multiple interactions with PpsE, and perhaps with other
members of the PDIM synthesis and transport machinery,
that compensate for this mutation.
Dominant Negative Effect of MmpL7 Domain 2 Requires
MmpL7
A simple mechanism to account for the dominant negative
effect of MmpL7 domain 2 expression is that the protein
interacts directly with PpsE in the cytoplasm in such a way as
to render the synthase inactive. Alternatively, because other
Figure 3. Identification of Residues in MmpL7 Domain 2 Required for PpsE Interaction
(A) Twelve MmpL7 domain 2 mutants defective for PpsE binding were isolated in a reverse two-hybrid screen. These amino acid substitutions are
displayed on a linear map of MmpL7 domain 2, with changes to amino acids other than proline or glycine in bold. Amino acid numbers correspond to
positions in full-length MmpL7. TM domains 7 and 8 are denoted by hatched bars.
(B) Yeast strains expressing the PpsE prey construct and various MmpL7 domain 2 bait plasmids were transferred onto X-gal indicator plates (inset), and
reporter activity was quantified from liquid cultures by monitoring b-galactosidase activity.
(C) Beads containing equal amounts of MmpL7 domain 2 and the I611S mutant were incubated with protein extracts containing myc-tagged PpsE and
washed. Bound proteins were eluted and separated by SDS-PAGE, and PpsE was visualized by Western blot using anti-myc antibodies. GST-coated
beads served as a negative control, and 1% of the protein extract added to the pulldown was loaded as a positive control (‘‘input’’).
DOI: 10.1371/journal.ppat.0010002.g003
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RND family members act as trimers [22,23], it is possible that
MmpL7 domain 2 may inhibit PpsE while in a complex with
full-length MmpL7. To distinguish between these two
possibilities, we tested whether the dominant negative effect
of MmpL7 domain 2 requires the presence of full-length
MmpL7. Interestingly, expression of MmpL7 domain 2 in
mmpL7 transposon mutant cells failed to inhibit PDIM
synthesis (Figure 5A, lane 4). Because the transposon mutant
may express fragments of MmpL7, we also created an M.
tuberculosis strain in which the full mmpL7 gene was removed
(Figure S1). Like the transposon mutant, the DmmpL7 strain
was unable to transport PDIM (Figure S1C) and was
insensitive to the dominant negative effect of MmpL7 domain
2 expression (Figure 5A, lanes 5 and 6). Expression of MmpL7
domain 2 was similar in all three strains (Figure 5B, lanes 2–
4). This finding demonstrates that the activity of cytoplasmi-
cally expressed MmpL7 domain 2 requires the presence of
wild-type MmpL7. Taken together, our results suggest that
MmpL7 domain 2 enters into a complex with endogenous
MmpL7 that interacts with PpsE, trapping the synthase in an
inactive state, thus inhibiting PDIM synthesis.
Discussion
PDIM, like other polyketide lipids, is a key molecule in the
pathogenesis of M. tuberculosis. In this study, we have
identified a novel interaction between MmpL7, a protein
required for PDIM transport, and PpsE, an enzyme required
for PDIM synthesis. Overexpression of the interaction
domain of MmpL7 causes a drastic defect in PDIM synthesis,
suggesting that this domain interacts with PpsE in vivo and
inhibits its activity. To our knowledge, this is the first report
of an interaction between a synthetic enzyme and its cognate
transporter. We propose that MmpL7 interacts with the
PDIM synthetic machinery to form a complex that coordin-
ately synthesizes and transports PDIM across the cell
membrane (Figure 6).
Interestingly, the dominant negative effect of domain 2 on
PDIM synthesis is dependent upon the presence of full-length
MmpL7. This strongly suggests that domain 2 incorporates
into a complex with endogenous MmpL7 and exerts its effect
only in this context. Like AcrB, an RND transporter in E. coli
[22,23], MmpL7 may normally act as a trimer or a higher
order oligomer, and a hybrid complex of full-length MmpL7
with domain 2 may trap PpsE in an inactive state.
Since MmpL7 is dispensable for PDIM production it is
curious that expression of domain 2 inhibits PDIM synthesis.
We propose a simple model to reconcile this paradox. In a
stepwise process of efficiently coordinating PDIM synthesis
and export, MmpL7 may possess both inhibitory and
activating activity on PDIM synthesis. For example, domain
2 may act to inhibit PpsE activity until the entire PDIM
synthesis–transport complex is assembled, at which point the
inhibition is relieved. Thus, MmpL7 domain 2 may exert its
Figure 4. MmpL7 Domain 2 Acts as a Dominant Negative Inhibitor of PDIM Synthesis In Vivo
(A) The indicated strains carrying either no plasmid (), control vector (vector), or a plasmid with MmpL7 domain 2 under the control of the constitutive
groEL2 promoter (MmpL7d2) were labeled with 14C-propionate. Surface-exposed lipids (S) were extracted by resuspension in hexanes, and cell pellets
(P) were harvested by centrifugation. Lipids from both fractions were extracted and separated by TLC under solvent conditions to separate PDIM (upper
panel, keto and methoxy forms) and SL-1 (lower panel).
(B) Top: lipids were extracted as in (A) from pellets of wild-type cells carrying either no plasmid (), the MmpL7 domain 2 expression plasmid (d2), or the
MmpL7 domain 2 expression plasmid with the I611S mutation (d2-I611S). Bottom: Western blot analysis was performed to confirm equivalent
expression of wild-type MmpL7 domain 2 and the I611S mutant by using antibodies against the hemagglutinin epitope tag.
(C) Complementation of an mmpL7 M. tuberculosis strain with the wild-type (mmpL7wt) or the I611S mutant mmpL7 (mmpL7 I611S). Surface-exposed
lipids (S) and lipids associated with the remaining cell pellet (P) were extracted and separated by TLC to resolve PDIM as in (A).
DOI: 10.1371/journal.ppat.0010002.g004
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dominant negative effect by stabilizing the inhibitory state of
this complex. In the absence of MmpL7, however, there is no
inhibition or activation of PDIM synthesis, therefore PDIM
synthesis is unaffected. This model would also explain why
the I611S mutation, when reconstituted into full-length
MmpL7, has no apparent effect. If the isoleucine residue is
important for inhibition of PpsE, then the I611S mutation
would not necessarily lead to a defect in PDIM synthesis or
transport.
Since MmpL7 and AcrB share the defining features of RND
transporters, it is tempting to draw parallels between the two
proteins. Both contain 12 putative TM helices with non-TM
loops between TM #1 and #2, and TM #7 and #8. In the crystal
structure of AcrB, the non-TM domains are predicted to be
periplasmic [22,23] and the TM domains form a central cavity
that is accessible to the cytoplasm. TM prediction algorithms
(TMPred, TMHMM) suggest that the non-TM domains of
MmpL7 are also periplasmic, although no experimental data
exist to validate this prediction. Since the interaction domain
of MmpL7 lies between TM #7 and #8, in order to interact
with PpsE, it must be accessible to the cytoplasm. There are a
number of ways in which this could occur. First, like the
glutamate transporter EAAT1 [28], the interaction domain of
MmpL7 may be reentrant through the membrane and thus
interact with PpsE. Alternatively, the PpsE protein may access
the extracellular portion of MmpL7 via a central pore created
by the MmpL7 TM domains. Finally, since MmpLs and AcrB
are distantly related members of the RND permease family,
the structure of MmpL7 may differ from AcrB, and the
orientation of MmpL7 in the membrane may be such that
domain 2 is located in the cytoplasm. Indeed, there are
examples of evolutionarily related transporters with opposite
membrane topology [29].
Since there is specificity in MmpL-mediated transport, it is
attractive to speculate that this specificity may be in part due
to the interaction with the cognate transporter. There is
evidence in both E. coli and Pseudomonas aeruginosa that when
the non-TM regions of two different RND permeases with
different drug efflux specificities are swapped, the respective
drug specificities are also switched [30,31]. We constructed
analogous chimeras between MmpL7 and MmpL8; although
these hybrids were expressed, they were nonfunctional (data
not shown). Despite the negative result, this suggests that
portions other than domains 1 and 2 are required for MmpL
function.
Given the results presented here, we propose that MmpL
proteins act not only as transporters but also as scaffolds to
couple polyketide synthesis and secretion. This model may
also provide a framework to explain the role of two other
RND family transporters in polyketide synthesis. In M.
tuberculosis, mmpL8 mutants are defective for SL-1 synthesis
and accumulate a partially lipidated precursor SL1278 [9].
Originally, we proposed that MmpL8 may transport SL1278
across the cell membrane, where subsequent enzymatic steps
would convert it to mature SL-1. However, in light of the
interaction between MmpL7 and PpsE, it is now tempting to
speculate that MmpL8 may similarly recruit a biosynthetic
enzyme required to complete the synthesis of SL-1 prior to
Figure 5. Dominant Negative Effect of MmpL7 Domain 2 Requires the
Presence of Full-Length MmpL7
(A) Wild-type cells, an mmpL7 transposon mutant (mmpL7 ), and a
complete mmpL7 knockout (DmmpL7) carrying either no plasmid () or
the MmpL7 domain 2 expression construct (þ). Labeled lipids were
extracted from pellets as described in Figure 4 and separated by TLC to
resolve PDIM.
(B) Western blot of MmpL7 domain 2 showing that it is expressed at
equivalent levels in the different M. tuberculosis strains.
DOI: 10.1371/journal.ppat.0010002.g005
Figure 6. Model of PDIM Synthesis and Transport
MmpL7 interacts with PpsE, a subunit of the Pps enzyme required for
PDIM synthesis. We propose that MmpL7 acts as a scaffold to recruit
PDIM synthesis machinery, including Pps and perhaps Mas, leading to
coordinate synthesis and transport of PDIM across the cytoplasmic
membrane (CM). Whether MmpL7, or other factors, are required for
delivery of PDIM through the peptidoglycan (PG) and mycolyl-
arabinogalactan (mAG) layers is unclear.
DOI: 10.1371/journal.ppat.0010002.g006
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transport. Likewise, an RND transporter in Streptomyces
coelicolor, ActII-ORF3, is also involved in the biogenesis of a
polyketide, c-actinorhodin [32]. Therefore, the coupling of
polyketide synthesis and transport via interactions between
synthases and cognate transporters may represent a general
mechanism utilized by RND family members to efficiently
export complex polyketides. This paradigm is reminiscent of
protein secretion where newly synthesized polypeptides are
co-translationally translocated across the membrane [33].
Coupling of synthesis and transport may be energetically
favorable while promoting specificity and directionality in
transport processes.
Materials and Methods
Strains and plasmids. M. tuberculosis cells (Erdman strain) were
cultured in 7H9 medium supplemented with 10% OADC, 0.5%
glycerol, and 0.1% Tween-80, or on 7H10 solid agar medium with the
same supplements except for Tween-80 [8]. Kanamycin (20 lg ml1)
and hygromycin (50 lg ml1) were used where necessary. All strains
and plasmids used in this study are described in Table S1.
Construction of M. tuberculosis knockout strain. The DmmpL7
(MJM39) mutant strain was created by homologous recombination
using specialized transducing phage phMJ1 [34]. This deletion
replaced all 2,763 bp of mmpL7 with a hygromycin resistance cassette,
and correct replacement of the gene was confirmed by Southern blot
analysis (Figure S1).
Yeast two-hybrid assays. The yeast two-hybrid screen was
performed as described [26], and expression of bait proteins in yeast
was confirmed by Western blotting using antibodies against LexA
(kind gift of R. Brent). Bait constructs using MmpL7 domain 2 and
MmpL8 domain 2 were created by PCR amplification and insertion
into pEG202. The prey library was constructed using random Erdman
genomic DNA fragments inserted into pjsc401. Positive interactors
were selected on media lacking leucine and then screened by blue–
white screening on agar plates containing X-gal (5-bromo-4-chloro-3-
indolyl b-D-galactoside). b-galactosidase activity was assayed in yeast
cells permeabilized with chloroform and sodium dodecyl sulfate as
previously described [35]. For reverse two-hybrid assays, error-prone
PCR was performed using Taq polymerase, 100 ng of the bait plasmid
containing mmpL7 domain 2 (pMJ2) as the PCR template, and 18 cycles
of amplification. Mutagenesis rate was approximately one mutation
per kilobase. Yeast homologous recombination was used to introduce
the mutant MmpL7 domain 2 PCR product into the bait vector. GFP
screening was performed visually by fluorescence microscopy.
GST pulldown binding assays. Recombinant MmpL7 domain 2–
GST, MmpL7 domain 2–I611S–GST, and GST alone were expressed
in E. coli strain DH5a by growing cultures to mid-logarithmic phase at
32 8C and inducing with 1 mM IPTG for 30 min. Cells were
centrifuged and resuspended in 50 mM Tris, 1 mM EDTA, 150 mM
NaCl, 1 mM PMSF, and 1 mM DTT, and lysed by sonication. Lysates
were cleared by centrifugation at 12,000 g and incubated with
Glutathione agarose beads (G 4510, Sigma, St. Louis, Missouri, United
States) at 4 8C overnight. Beads were washed four times with PBS, 1
mM EDTA, and 0.5% Triton X-100, and then stored as a 50% slurry
in 50 mM Tris, 1 mM EDTA, 500 mM NaCl, 20% glycerol, and 0.5%
Triton X-100. PpsE-myc was expressed in M. smegmatis, and lysates
were prepared by bead-beating cells into binding buffer (20 mM Tris,
1 mM EDTA, 150 mM NaCl, 1 mM PMSF, and 1 mM DTT). Lysates
were incubated with 50 ll of protein-coated beads overnight at 4 8C,
washed three times in binding buffer, and resuspended in SDS sample
buffer. Samples were boiled to elute all proteins off the beads and
resolved on 7.5% SDS-PAGE gels. PpsE-myc was detected by Western
blotting using 9E10 monoclonal antibodies (kind gift of J. M. Bishop).
Biochemical analysis of PDIM and SL-1. M. tuberculosis cultures
were labeled with 14C-propionate, which is incorporated into both
PDIM and SL-1. Surface-exposed lipids were extracted by resuspend-
ing the cells in hexanes and gently sonicating [9]. Cell pellets,
containing the remainder lipids, were harvested by centrifugation.
Lipids from both fractions were extracted by the Bligh-Dyer method
[36] and analyzed by separation on 10 cm 3 10 cm HPTLC plates
(Alltech Associates, Deerfield, Illinois, United States) by using either
hexanes/ether (9:1) to resolve PDIM or chloroform/methanol/water
(60:30:6) to resolve SL-1. Lipid spots on TLC plates were quantified
using a phosphorimager.
Protein preparation and analysis. M. tuberculosis cells were grown
into mid-logarithmic phase and harvested by centrifugation. Cell
lysates were separated by SDS-PAGE using 12% polyacrylamide gels.
Proteins were visualized by immunoblotting using monoclonal
antibodies against the hemagglutinin epitope tag (HA.11, Covance,
Berkeley, California, United States). Loading was normalized by total
protein, and efficiency of transfer was confirmed by Ponceau S
staining of the nitrocellulose membrane.
Supporting Information
Figure S1. Creation of DmmpL7 in M. tuberculosis by Specialized
Transduction
(A) Map of the mmpL7 region in wild-type and the DmmpL7 mutant
showing the restriction sites and probe location for Southern blot.
Genomic DNA from both wild-type and DmmpL7 was digested with
BamHI, and the blot was probed with a 1,029-bp 59 flank to mmpL7
revealing a 2,636-bp fragment for wild-type and a 4,700-bp fragment
for the mutant.
(B) Southern blot of BamHI-digested genomic DNA from indicated
strains.
(C) Surface-exposed lipids (S) and lipids associated with the
remaining cell pellet (P) were labeled and extracted from wild-type
and DmmpL7 cells as described in Figure 4A and then separated by
TLC to resolve PDIM.
Found at DOI: 10.1371/journal.ppat.0010002.sg001 (29 KB PDF).
Table S1. Strains and Plasmids Used in This Study
Found at DOI: 10.1371/journal.ppat.0010002.st001 (71 KB DOC).
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